La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Precigen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Precigen..

Precigen (NASDAQ:PGEN) Azioni, Catena delle Opzioni

PRECIGEN INC

Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen Inc

Pigeon Corp

<a href="https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm">https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm</a>

Macro Economic Events

News

Economics

Federal Reserve

Federal Reserve Board Requests Comment On Targeted Proposal To Revise Its Supervisory Rating Framework For Large Bank Holding Companies To Address The "Well Managed" Status Of These Firms

Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and raises the price target from $54 to $55.

Price Target

Analyst Ratings

HRMY

Deutsche Bank Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $55

Macquarie analyst Paul Golding downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Outperform to Neutral and maintains the price target from $15 to $15.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Macquarie Downgrades Core Scientific to Neutral, Maintains Price Target to $15

Deutsche Bank analyst Melissa Weathers initiates coverage on Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy rating and announces Price Target of $150.

Initiation

Deutsche Bank Initiates Coverage On Micron Technology with Buy Rating, Announces Price Target of $150

Goldman Sachs analyst Corinne Johnson reinstates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and announces $55 price target.

Goldman Sachs Reinstates Buy on Avidity Biosciences, Announces $55 Price Target

As the race for satellite internet heats up, major players like Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are staking their claim in a market projected to be worth <a href="https://www.benzinga.com/news/space/25/06/46012441/amazon-retrains-warehouse-workers-for-satellite-jobs-it-really-is-life-changing-says-project-kuiper-technician">$40 billion by 2030.</a>
Bank of America Securities analyst Justin Post <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Buy</a> on Amazon with a price forecast of $248 on Thursday.
Project Kuiper has remained a top management growth initiative despite Amazon&#8217;s cost-focused agenda, and satellite launches began in the second quarter, Post noted. On its Website, Amazon has indicated that it expects to offer consumer service in late 2025, though timing is still uncertain, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46252872/why-amazon-lags-its-peers-in-2025" rel="noreferrer noopener">Why Amazon Lags Its Peers In 2025</a>
In his report, the analyst refreshed his views on launch costs and near-term expense impact from network build, the Project Kuiper business, potential synergies with Amazon, competitive landscape, revenue potential, and potential subscriber breakeven level assuming a 5-year satellite replacement cycle.
Amazon&#8217;s FCC license calls for 1,618 satellites to be deployed by July 2026, though Post noted an extension is possible given launch delays. Amazon completed the first two launches with 54 satellites in the second quarter of 2025, and the analyst expects an accelerated launch rate in the second half of 2025 (3 launches in the third quarter) and 2026.
He estimated that Amazon could spend $23 billion to build its entire constellation, using various public industry estimates, excluding consumer equipment costs.
In the near term, Post estimated over $600 million in constellation expense in the second quarter, ramping to ~$800 million in the third quarter and then growing to $1.1 billion in the fourth quarter of 2025 (before capitalization starts in the first quarter of 2026).
Amazon&#8217;s website indicates that consumer availability could begin in the fourth quarter, but a delay seems possible, the analyst said. He also had a scenario where capitalization starts later, in the third quarter of 2026.
He noted that 2.6 billion people globally lack broadband internet access, and BCG sees a $40 billion 2030 revenue potential for the global satellite communications service market.
Based on Post&#8217;s market assumptions, and assuming Amazon has just a 30% consumer share (Starlink already has 6 million subscribers), the analyst noted a $7.1 billion 2032 revenue potential for Amazon.
He also expects Kuiper to have synergies with Amazon&#8217;s logistics network, and the project to generate additional revenues from AWS&#8217;s enterprise and government customers. Post noted a compelling opportunity and potentially strong long-term margins given high start-up costs.
Post projected fiscal 2025 sales of $696.81 billion and EPS of $6.07.
AMZN Price Action: Amazon.com shares were up 0.09% at $222.75 at the time of publication Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46333941/meta-has-gained-26-in-2025-can-the-rally-continue" target="_blank" rel="noreferrer noopener">Meta Has Gained 26% In 2025, Can The Rally Continue?</a></li>
</ul>
Photo: Shutterstock

Reiteration

Tech

Trading Ideas

AMZN

How Project Kuiper Could Reshape Amazon's Future, Tap Into $40 Billion Demand

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) supplemental Biologics License Application (sBLA) for Spikevax, the company&#8217;s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
The company&#8217;s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46168811/modernas-mrna-flu-vaccine-outperforms-standard-shots" rel="noreferrer noopener">Moderna&#8217;s mRNA Flu Vaccine Outperforms Standard Shots</a>
&#8220;COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,&#8221; said Stéphane Bancel, CEO of Moderna. &#8220;We appreciate the FDA&#8217;s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.&#8221;
Moderna<a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" rel="noreferrer noopener"> expects</a> to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) have requested that London's Court of Appeal reverse a previous decision that found their COVID-19 vaccine to be in violation of a Moderna patent.
In July 2024, the High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech's Comirnaty <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">vaccine had infringed on it</a>.
Reuters reported that Pfizer and Moderna are trying to challenge a ruling that upheld a patent, after Judge Richard Meade allowed them to appeal his decision.
They argue that Moderna&#8217;s mRNA technology was simply a clear next step based on earlier research, so the patent shouldn&#8217;t be valid. However, Moderna believes the judge made the right decision and that the ruling should remain in place.
An alliance of medical and public health organizations filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Kennedy has launched an "assault on science, public health, and evidence-based medicine" through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children <a href="https://www.benzinga.com/news/health-care/25/07/46303191/medical-groups-sue-rfk-jr-for-assault-on-science-over-unlawful-covid-19-vaccine-rollbacks" target="_blank" rel="noreferrer noopener">and pregnant individuals</a>.
According to a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration's (FDA) top vaccine official, overruled agency scientists to limit the approval of two COVID-19 vaccines, despite internal recommendations to clear <a href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" target="_blank" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">the balance of risks and benefits</a>.
Price Action: MRNA stock is up 3.60% at $33.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46345543/klotho-stock-delivers-1222-biotech-blowout-opportunity-or-bubble" target="_blank" rel="noreferrer noopener">Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Movers

General

BNTX

MRNA

NVAX

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

Goldman Sachs analyst Corinne Johnson reinstates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and announces $33 price target.

AVBP

Goldman Sachs Reinstates Buy on ArriVent BioPharma, Announces $33 Price Target

Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy and announces $10 price target.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Goldman Sachs Reinstates Buy on Amylyx Pharmaceuticals, Announces $10 Price Target

HSCS

HeartSciences Shares Halted On Circuit Breaker To The Downside, Stock Now Up 19.0%

CIGL

Concorde International Group Shares Halted On Circuit Breaker, Stock Now Down -86.5%

B. Riley Securities analyst Lucas Pipes maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $15 to $22.

IREN

B. Riley Securities Maintains Buy on IREN, Raises Price Target to $22

B. Riley Securities analyst Nick Giles maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and lowers the price target from $3 to $2.

B. Riley Securities Maintains Buy on Canaan, Lowers Price Target to $2

<a href="https://www.dallasfed.org/fed/events/2025/25waller">https://www.dallasfed.org/fed/events/2025/25waller</a>

Macro Notification

Politics

Fed's Waller Says Tariffs Increase Prices One Time, Central Banks Can Look Through That;  Tariff Effects Not Zero But Are Not Large Either; Has Been Arguing A Pretty Restrictive Policy Rate Can Come Down; Unemployment Is Around Long Run Level; Retierates Case For Why July Rate Cut Could Happen, Says An Easing Would Not Be Political

Correction: Needham analyst John Todaro downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Hold.(Price Target removed)

Correction: Needham Downgrades Core Scientific to Hold (Price Target removed)

B. Riley Securities analyst Lucas Pipes maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and lowers the price target from $18 to $17.

BTDR

B. Riley Securities Maintains Buy on Bitdeer Technologies, Lowers Price Target to $17

<a href="https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html" title="https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html">https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html</a>

Global

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

'Some of Iran's Enriched Uranium Survived Attacks, Israeli Official Says' - NY Times

B. Riley Securities analyst Christopher Souther maintains Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) with a Buy and raises the price target from $6 to $10.

AMPX

B. Riley Securities Maintains Buy on Amprius Technologies, Raises Price Target to $10

On Wednesday, Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported net sales of $26.44 billion for the retail month of June, which includes the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46333348/costco-shares-rise-after-sales-climb-8-in-june" rel="noreferrer noopener">five-week period ending July 6</a>.
Net sales for the month were up 8% on a year-over-year basis.
The membership-based retailer said total company comparable sales were up 5.8%.
Bank of America (BofA) Securities writes overall, COST's June U.S. core comp came in at +5.5%, slightly below the Street's +6.0% per consensus Metrix, but ahead of buy-side expectations of ~5.0%.
U.S. traffic was +2.8% and total enterprise-wide traffic was +3.4%, while average ticket increased +2.8% YOY (ex-gas deflation and FX).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46348041/is-costcos-winning-streak-built-to-last-during-economic-turmoil" rel="noreferrer noopener">Is Costco&#8217;s Winning Streak Built To Last During Economic Turmoil?</a>
Looking ahead, the tough comparisons due to high gold prices should ease by August. BofA also expects the negative impact from store overlap (cannibalization) to gradually lessen to a more typical range of 20-30 basis points by year-end.
Additionally, the drop in store traffic caused by lower gas prices year-over-year is likely to have peaked, as the steep comparisons should ease by August or September. Current gas prices also suggest mild inflation by October.
As a result, the negative sentiment from momentum investors who viewed Costco as a &#8220;source of funds&#8221; to sell should start to fade, although BofA said they will still be watching how growth stocks perform compared to value stocks and the Russell 2000.
Analyst Christopher Horvers maintains an Overweight rating on Costco, viewing it as a key investment due to its strong global performance, consistent market share growth and exposure to a rebound in large-item spending, which accounts for approximately 20% of its core sales.
He also notes the early benefits of Costco&#8217;s growing advertising business. Horvers says Costco stands out even among top consumer companies.
Unlike other major retailers, Costco has been successful in every country it has entered. Its membership-based model is one of the strongest in retail, comparable to leading auto parts retailers, with Costco clearly leading the market.
BofA maintains the Overweight rating with a price forecast of $1,115. Check out <a href="https://www.benzinga.com/quote/COST/analyst-ratings" target="_blank" rel="noreferrer noopener">other analyst stock ratings</a>.
Price Action: COST stock is down 0.58% at $976.38 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46346078/microsoft-stock-is-trending-thursday-whats-going-on" target="_blank" rel="noreferrer noopener">Microsoft Stock Is Trending Thursday: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Retail Sales

COST

BofA Sticks With Overweight On Costco, Sees Easing Headwinds Ahead

B. Riley Securities analyst Christopher Souther maintains Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a Buy and raises the price target from $12 to $17.

ENVX

B. Riley Securities Maintains Buy on Enovix, Raises Price Target to $17

Earnings

Press Releases

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Offerings

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Comments

Precigen

Precigen (PGEN) Opzioni

Precigen (NASDAQ:PGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO